Image Ben Hargreaves Digital AI is enabling the rise of sophisticated digital therapeutic... Ben Hargreaves explores the capability of AI and machine learning to produce ever more accurate and effective digital therapeutics. Market Access Is pharma market on the rebound in 2023? As the financial markets have been roiled by inflation and a minor banking crisis, the pharma industry experienced a period where M&A largely disappeared and investment into biotechs dr Sales & Marketing The drug pricing discussion that won’t disappear Discussions of the pharma industry in the political sphere have lingered on pricing for a number of years. R&D Manufacturing key to overcoming the next pandemic Ben Hargreaves looks at the way governments are preparing for a future pandemic. Load more results
Digital AI is enabling the rise of sophisticated digital therapeutic... Ben Hargreaves explores the capability of AI and machine learning to produce ever more accurate and effective digital therapeutics.
Market Access Is pharma market on the rebound in 2023? As the financial markets have been roiled by inflation and a minor banking crisis, the pharma industry experienced a period where M&A largely disappeared and investment into biotechs dr
Sales & Marketing The drug pricing discussion that won’t disappear Discussions of the pharma industry in the political sphere have lingered on pricing for a number of years.
R&D Manufacturing key to overcoming the next pandemic Ben Hargreaves looks at the way governments are preparing for a future pandemic.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
